Cervical cancer is leading to death among women worldwide and the primary cause of cervical cancer is human papillomavirus (HPV) infection. The heterogeneity of patients in various aspects, such as tumorigenesis, body immune response and immune evasion mechanisms by different virus subtypes, represent a challenge to achieve effective prevention and precise treatment. Therefore, it has become a global concern to screen for biomarkers and therapeutic target for HPV associated cervical cancer that are less toxic agents and improve survival rate. In the present study, we sought to identify potential immune related biomarkers based on publicly available transcriptomic, and epigenetic datasets and study their correlation with immune cell infiltration and finally study their expression in different high-risk HPV subtypes. Initially, we identified 328 differentially expressed genes and 830 differentially methylated genes. Analysis showed that those genes are involved in the defense response process and Human T-cell leukemia virus 1 infection pathway. Twenty genes were found to be immune checkpoint genes and therefore are potential biomarkers that may play a crucial role in HPV associated cervical cancer. Using enrichment based on publication, we found that these biomarkers are involved in CD8 T-cell, Tregs cell, Natural killer cell pathways and immunotherapy targets. Notably, most of the ICGs correlated with CD8 T-cell and NK cell infiltration. Furthermore, the expressions of KDR, SMAD3, WNT9A, IL15, FOXP3 and CD96 showed different expression levels between high-risk HPV subtypes. Thus, these biomarkers may enable better response for targeted immunotherapy.